Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Sun Tzu who wrote (12063)	10/4/2021 2:38:38 PM
From: jpdunwell	Read Replies (1) \| Respond to of 26758

I have to agree with Logain's original assertion here, as obtaining a new patent for Ivermectin at this stage would be basically impossible based on prior art. It's already difficult to get patents for re-purposed drugs, but in this particular case, there is so much public domain information out there already, it would be insurmountable. It boils down to there's no money to be had here. I do find it ironic how much media buzz and stir and excitement there is over the new Merck drug, vs. how much censorship and outright vitriol there is towards ivermectin. Most of those opinions are based on complete ignorance in both cases, and completely shaped by the media and message this administration wants the populace to hear. People should think long and hard (and search and study all the data behind both of these examples as well) about all the reasons behind that, and how we got to this state.